The Roman Colosseum and Arch of Constantine.

The 15th International Myeloma Workshop took place September 23-26, 2015, in Rome, Italy.

Combo demonstrates potential in MM



multiplemyeloma.jpg
Micrograph showing MM

Early results of a pilot study indicate that a 3-agent combination regimen can produce responses in patients with relapsed or refractory multiple myeloma (MM). The treatment consists of carfilzomib, dexamethasone, and pelareorep (Reolysin), a proprietary isolate of human reovirus (Type 3 Dearing strain). All 8 evaluable patients treated with this regimen... [Read Article]

mAb produces ‘encouraging’ results in MM



multiple_myeloma_bone_marrow_aspirate_showing_230.jpg
Micrograph showing
multiple myeloma

Combination therapy incorporating a novel monoclonal antibody (mAb) can provide “encouraging, long-lasting tumor control” in heavily pretreated patients with relapsed/refractory multiple myeloma (MM), according to investigators. The mAb, MOR202, was also considered to be well-tolerated in this ongoing phase 1/2a study. Early results from this study were presented at the... [Read Article]